Targeting new markets

How to reach us

M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
Germany

T. +49 (0)30 347 47 44 14
F. +49 (0)30 347 47 44 17
E.

For medical consultation appointments contact: https://www.m1-beauty.de/termine/

Contact

Data protection*

Latest news

| Investor News

  • Supervisory Board adopts the 2021 annual financial statements of M1 Kliniken AG, which have been audited with unqualified audit opinions
  • Turnover almost doubles to almost 315 million euros. Group operating result (EBIT) almost tripled to €12.1 million (€4.4 million in 2020)
  • The Supervisory Board and the Executive Board propose to the Annual General Meeting that the balance sheet profit be carried forward in full to new account. Investments in sustainable growth planned.

| Investor News

M1 Kliniken AG publishes preliminary figures for the 2021 financial year. In the past financial year, the M1 Group was able to significantly expand its market position in the field of beauty medicine and opened seven new specialist centres in the German home market alone. The subsidiary Haemato AG set a cornerstone for the development of the own-brand business with the in-licensing of a botulinum toxin product from Huons Biopharma. The start of the clinical approval trial is planned for the second half of 2022.

| Investor News

  • Average daily sales in November 2021 in the German practice network again at record level
  • All specialist centres open
  • With four more openings in Germany and Australia, M1 will operate a total of 47 specialty centres by year-end 2021

| Investor News

  • Group revenue rises to EUR 237 million (EUR 82 million in Q3-2020)
  • Beauty: treatment numbers at high level; record revenue in German practice network in October 2021; no negative impact from rising incidence rate of the Corona pandemic
  • Group EBITDA amounts to EUR 13.3 million (previous year: EUR 8.8 million); EBIT amounts to EUR 9.1 million (previous year: EUR 5.8 million); EBIT margin in the German practice network in the target corridor of 15-20% despite large number of new openings